While biosimilars have yet to take off in the U.S., top credit rating agency Moody's remains optimistic of the future market opportunity for the biologic copycats, calling the competition "a rising headwind for branded pharmaceutical companies" in an Oct. 4 report.
The agency's analysis highlighted five pharmaceutical giants that stand to gain the most from biosimilars, as well as four companies at the highest risk from these drugs.
